WT1 126-134 Peptide Vaccine

DRACPC ID  DRACPC0096

Active Ingredients   WT1 126-134 Peptide Vaccine

Description  A synthetic peptide vaccine consisting of the amino acids 126 through 134 of the human Wilms' Tumor protein-1 (WT1) with potential antitumor activity. WT1, a tumor associated antigen, is overexpressed in most types of leukemia and in a variety of solid cancers. Vaccination with WT1 126-134 peptide vaccine may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation.

Synonyms  WT-1: 126-134; WT1 126-134 Peptide Vaccine

Type  Biotech

Disease  Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  Not available

Molecular Weight  Not available

Active Sequence  RMFPNAPYL

Sequence Length  9

Modification  None

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  Not available

InChI  Not available

InChI_Key Not available

SMILES  Not available

External Codes


PubChem CID  Not available

DrugBank Accession Number  Not available

NCI Thesaurus Code  C61442  

UNII  Not available  

CAS  Not available



Drug approval


Drug indication
    Investigated for use/treatment in Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00433745 Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies Myelodysplastic Syndrome; Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML) Phase 2 Treatment
NCT00488592 Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML) Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.